The QualityStocks Daily Tuesday, September 18th, 2018

Today's Top 3 StockMarketWatch

StockMarketWatch (VKTX) +87.30%

CannabisNewsWire (PRVCF) +53.33%

StocksToBuyNow (MTEHF) +30.24%

The QualityStocks Daily Stock List


Penny Stock Tweets, Advanced Equity Research, Green Market Report, TipRanks, The Street, FXStreet, Micro Small Cap, YCharts, 4-Traders, Capital Cube, Street Register, Market Screener, Wallet Investor, InvestorsHub, Micro Cap Daily, Equities, Barchart, StockInvest, TradingView, Finance Registrar, Investor Place, Insider Financial, Stockhouse, and MarketWatch reported on WEED, Inc. (BUDZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

WEED, Inc. is a multi-national, multi-faceted, vertically-integrated world class cannabis organization. The Company is committed to its worldwide goals and outreach across the full spectrum of the cannabis industry to find treatments, therapies and medical cures utilizing the Cannabaceae plant family. Listed on the OTCQB, WEED is headquartered in Tucson, Arizona.

The Company is structured as a holding company. It does business via its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to achieve and promote its international brand. WEED does not grow, harvest, produce, or sell any substance in violation of US Federal law under The Federal Controlled Substances Act. Moreover, the Company meets all standards of international law for WEED, Inc. and its subsidiaries in foreign locations.

This past March, WEED announced that it completed the earlier announced purchase of its 4-acre property in La Veta, Colorado. This is where its wholly-owned subsidiary, Sangre AgroTech, is engaged in the previously announced 5-year, $15+ million Cannabis Genomic Study.

In association with the La Veta property, WEED received unanimous approval of the La Veta Town Council for a Commercial Redevelopment Permit to commence planned renovations and construction of the Bioscience Research Center for the operations of Sangre AgroTech to convert the existing buildings into laboratory facilities required for Sangre to conduct its research, along with additional security and ground buildout.

Sangre AT, LLC, dba Sangre AgroTech, has started a five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, through creating a worldwide genomic classification of the entire plant. By targeting cannabis-derived molecules, which stimulate the endocannabinoid system, Sangre AgroTech’s research team plans to develop scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines. The aim of the research is to identify, collect, patent, and archive a collection of highly-active medicinal strains.

WEED has established WEED Israel (Cannabis) Ltd. as a wholly-owned subsidiary of WEED, Inc (USA).  WEED Israel (Cannabis) Ltd. is now in negotiations with major universities, hospitals, charitable organizations, Kibbutz, and private & public entities to establish a true "SEED-TO-SALE" company from the Holy Land.

WEED, Inc. (BUDZ), closed Tuesday's trading session at $3.03, off by 5.01%, on 319,417 volume with 564 trades. The average volume for the last 3 months is 188,135 and the stock's 52-week low/high is $0.93/$15.199.


Know Labs, Inc. (KNWN)

High Rising Stocks, Amigo Bulls, Dividend Investor, OTC Markets, Spotlight Growth, Insider Tracking, Stockhouse, Business Wire, 4-Traders, Open Insider, Marketbeat, last10k, Stockwatch, VentureLine, MarketWatch, Simply Wall St, Stockopedia, Investors Hangout, TradingView, Insider Monkey, InvestorsHub, Street Insider, Wallet Investor, and YCharts reported on Know Labs, Inc. (KNWN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The Company invented a cutting-edge technology called Bio-RFID, which will provide information to consumers about their health and wellness. Furthermore, Know Labs uses its proprietary ChromaID technology to identify unique molecular signatures in materials. The Company formerly went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May of this year. Know Labs lists on the OTC Markets Group’s OTCQB.

Know Labs develops technology platforms that harness light and radio waves to uncover distinctive insights about the world. Its technology directs electromagnetic energy by way of a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye.

ChromaID and Bio-RFID scanner modules can be integrated into a variety of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses, which could only previously be performed by invasive and/or large and costly lab-based tests.

Last month, Know Labs announced its UBAND™ real time wearable calorie counter wrist band. The Calorie Counter UBAND is built upon the Company’s recent invention, which detects blood glucose non-invasively. Currently, Know Labs has 12 issued patents with 20 pending, covering its specialty.

Last week, Know Labs announced that James Anderson, MD, joined the Company as Medical Director. Additionally, Dr. Anderson will serve as Chairman of Know Labs’ Medical, Scientific and Regulatory Affairs Advisory Board.

James H. Anderson, Jr., M.D., FFPM, FACE, is a diabetologist and endocrinologist. He has been in military medicine and the pharmaceutical industry for over four decades. Dr. Anderson started his Fellowship in Endocrinology and Metabolism at LSU. He completed it at the Medical College of Virginia in Richmond.

Know Labs, Inc. (KNWN), closed Tuesday's trading session at $4.52, up 0.11%, on 4,428 volume with 23 trades. The average volume for the last 3 months is 37,326 and the stock's 52-week low/high is $0.93/$15.199.


Nu-Med Plus, Inc. (NUMD)

Stockhouse, The StreetWise Reports, MarketWatch, Stockopedia, Business Insider, Morningstar, GuruFocus, CapitalCube, OTC Markets, Marketwired, Investing News, Street Insider, The Street, Last10k, TradingView, Wallmine, Stockwatch, Wallet Investor, and VentureLine reported on Nu-Med Plus, Inc. (NUMD), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Nu-Med Plus, Inc. investigates and develops applications of Nitric Oxide technologies in the medical field. The Company formed to explore medical applications of newly developed technologies. Its business strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. A medical device enterprise, the Company has its corporate office in Salt Lake City, Utah.

Inhaled Nitric Oxide (INO) is a medically essential gas. It is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems. INO may have future applications for an assortment of other diseases and medical complications that are currently being investigated. Nu-Med has the capability to deliver high purity Inhaled Nitric Oxide (INO) to the patient at point of use.

Nu-Med Plus’ markets include neonatal complications, COPD, Tuberculosis, Malaria, and ARDS (a severe lung syndrome with no known cure). The Company’s team has developed a new Nitric Oxide (NO) gas delivery system. This system provides a continuous intra-breath concentration of therapeutic NO to medically supervised patients who are on ventilators in a hospital setting.

Nu-Med Plus announced this past June its patent filing for its pioneering chemically reactive coating. The coating ensures that only a contaminant free nitric oxide, a life saving drug for neonates, reaches the patient.

The Company has developed an innovative method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing. Fundamentally, the coating removes toxic contaminants that are found in nitric oxide delivery systems.

Last week, Nu-Med Plus announced that Dr. Ronald Day will incorporate the recently developed Nu-Med Plus 100 nitric oxide delivery device into a yet-to-be disclosed research study. Dr. Day is a pediatric cardiologist at the University of Utah. He is a prominent researcher examining, among other studies, nitric oxide to treat children suffering from pulmonary hypertension.

Nu-Med Plus, Inc. (NUMD), closed Tuesday's trading session at $0.96, even for the day, on 600 volume with 2 trades. The average volume for the last 3 months is 1,205 and the stock's 52-week low/high is $0.23/$1.0099.


First Acceptance Corporation (FACO)

Zacks, Amigo Bulls, OTC Markets, Stockwatch, Stockopedia, Penny Stock Hub, TradingView, Simply Wall St, 4-Traders, MarketWatch, YCharts, Barchart, InvestorsHub, Stockhouse, The Street, and CapitalCube reported on First Acceptance Corporation (FACO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

First Acceptance Corporation is mainly a retailer, servicer and underwriter of non-standard personal automobile insurance. The Company currently conducts its insurance servicing and underwriting operations in 13 states. It operates only as an insurance agency in three states. In addition, First Acceptance is licensed as an insurance company in 13 states where it does not conduct any business. The Company has its head office in Nashville, Tennessee. First Acceptance lists on the OTC Markets’ OTCQX.

In essence, First Acceptance issues non-standard automobile insurance policies to individuals based on their inability or unwillingness to obtain insurance coverage from standard carriers because of an array of factors. These include their payment history or need for monthly payment plans, failure to maintain continuous insurance coverage, or driving record.

The Company’s insurance operations generate revenue from selling non-standard personal automobile insurance products and related products in 16 states. The Company chiefly distributes its products through its retail locations, as well as through a call center and the Internet.

At March 31, 2018, First Acceptance leased and operated 349 retail locations and a call center staffed by employee-agents. These employee-agents primarily sell non-standard personal automobile insurance products underwritten by First Acceptance as well as certain commissionable ancillary products. The Company’s products include Auto Insurance, Renters Insurance, Motorcycle Insurance, Roadside Assistance, Hospital Benefits, Ohio Bond Policy, and Med Pay.

Last month, First Acceptance reported its financial results for the three and six months ended June 30, 2018. Income before Income Taxes, for the six months ended June 30, 2018 was $13.5 million, versus $96,000 for the six months ended June 30, 2017.

Net Income for the six months ended June 30, 2018 was $10.2 million, versus a Net Loss of $173,000 for the six months ended June 30, 2017. Basic and Diluted Net Income per Share were $0.25 for the six months ended June 30, 2018, versus a Basic and Diluted Net Loss per Share of $0.004 for the same period in the year prior.

First Acceptance Corporation (FACO), closed Tuesday's trading session at $1.15, up 0.88%, on 195,800 volume with 17 trades. The average volume for the last 3 months is 23,267 and the stock's 52-week low/high is $0.75/$1.4989.


International Battery Metals Ltd. (RHHNF)

Stockwatch, Stockhouse, and OTC Markets reported on International Battery Metals Ltd. (RHHNF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

An advanced technology company, International Battery Metals Ltd. specializes in lithium extraction from oilfield brines. It is in the process of creating and applying intellectual property (IP) related to lithium extraction from oilfield brines for petro-lithium extraction projects. The Company previously went by the name Rheingold Exploration Corp. It changed its name to International Battery Metals Ltd. in August of last year.

International Battery Metals is headquartered in Vancouver, British Columbia. Its corporate mission is to enable the Battery Industry to reach $100/kWh within the next five years and realize the complete potential of renewable energy. The Company’s shares trade on the OTC Markets Group’s OTCQB.

International Battery Metals signed a definitive share exchange agreement with Selective Absorption Lithium (SAL), a unique technology developer. SAL has developed advanced patent pending technology designed to deal with the demanding conditions associated with oil field brine resources. SAL’s new technology is founded on first generation selective absorption technology, which Dr. Burba and Dr. Bill Bauman invented and sold to FMC Corporation in the early 1990’s.

International Battery Metals’ innovative extraction process is environmentally friendly and low cost. In addition, it has the potential to produce high-quality, commercial grade lithium at a much quicker rate than the present industry standards.

Earlier this month, International Battery Metals announced that it entered into a binding Share Exchange Agreement (SEA), with North American Lithium, Inc. (NAL) and Selective Adsorption Lithium (SAL), dated March 4, 2018. International Battery Metals will acquire intellectual property (IP) related to lithium extraction from oil field brines for petro lithium extraction projects.

NAL is a California corporation. NAL has developed inventive technology, which permits direct extraction of lithium from complex brines including those found in oil fields. SAL has advanced this technology. SAL owns IP related to oil field brines.

This week, International Battery Metals announced that it retained the services of Hunter Stuart Energy Advisers, Inc. Hunter Stuart is a United States headquartered oil & gas advisory firm. The Company has retained Hunter Stuart for lithium property acquisitions in the U.S.

In addition, this week, International Battery Metals announced that Selective Adsorption Lithium (SAL) the technology company being acquired by International Battery Metals filed for patent protection at the U.S. Patent and Trademark Office (USPTO) for its lithium extraction process. The patent application, "Extraction process control methods and apparatuses," will protect directly the extraction process in the U.S. as SAL prepares to file the application globally.  


International Battery Metals Ltd. (RHHNF), closed Tuesday's trading session at $0.134, up 4.29%, on 59,753 volume with 15 trades. The average volume for the last 3 months is 59,753 and the stock's 52-week low/high is $0.1087/$1.11.


Aurania Resources Ltd. (AUIAF)

Penny Stock Hub, 4-Traders, MarketWatch, Stockhouse, Barchart, GuruFocus, Morningstar, Investors Hangout, Investing News Alerts, StockCharts, Streetwise Reports, Stockwatch, OTC Markets, Wallet Investor, TradingView, and Junior Mining Network reported on Aurania Resources Ltd. (AUIAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aurania Resources Ltd. is a junior exploration mining company based in Toronto, Ontario. The Company engages in the identification, evaluation, acquisition and exploration of mineral property interests. Its focus is on precious metals and copper. Aurania Resources’ shares trade on the OTC Markets’ OTCQB.

The Company’s flagship asset is The Lost Cities-Cutucu Project. It is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador. The Lost City Project is in the south-eastern part of the Republic of Ecuador, in the Province of Morona-Santiago.

The Project comprises circa 208,000 hectares in 42 concessions occupying the central part of the Cordillera de Cutucu.  The concessions extend roughly 95 km along the Cordillera.

Aurania Resources also has three projects in Canton Valais, Switzerland. These are Siviez (Uranium, Copper and Gold), Marécottes (Uranium), and Mont Chemin (Gold). All of these projects are 100 percent held through Aurania’s wholly-owned subsidiary AuroVallis SARL.

Aurania Resources reported in May 2018 the discovery of a new epithermal zone roughly eight kilometers south of the "Crunchy Hill" area. This new discovery is called "Yawi". In addition, two diatremes (breccia bodies) were found in close by outcrop. Aurania states that presumably there is a geological connection between the diatremes and the mineralization.

Rocks in the region are clay-and sericite-altered.  Preliminary XRF (x-ray fluorescence) analysis indicates anomalously high levels of mercury and arsenic in selected samples. These are natural pathfinder elements for precious metals. They can be used to vector into the mineralization.

Last week, Aurania Resources reported that an extension to its Crunchy Hill target was confirmed in pathfinder element enrichment in soil over a one-kilometer trend. Pathfinder element enrichment outlines the shape of what appears to be an underlying vein system which, combined with other datasets, is being used to refine the form and depth of a possible epithermal gold-silver target.

Crunchy Hill is Aurania’s most advanced target in its Lost Cities — Cutucu Project in Ecuador. It will be the initial target to be drilled in late 2018.

Aurania Resources Ltd. (AUIAF), closed Tuesday's trading session at $1.6212, up 0.07%, on 265 volume with 3 trades. The average volume for the last 3 months is 6,987 and the stock's 52-week low/high is $1.0249/$6.0633.


Namaste Technologies, Inc. (NXTTF)

OTC Markets, MarketWatch, InvestorsHub, Stockhouse, InvestorsHangout, TradingView, and Daily Marijuana Observer reported on Namaste Technologies, Inc. (NXTTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Namaste Technologies, Inc. is the largest online retailer for medical cannabis delivery systems globally. The Company distributes vaporizers and smoking accessories by way of e-commerce sites in 26 countries and with 5 distribution hubs located worldwide. Namaste’s long term strategy is to become a top supplier of legal cannabis products as the cannabis market is legalized in each nation. Namaste Technologies is headquartered in Toronto, Ontario. The Company’s U.S. office is in Jupiter, Florida and its Bahamas office is in Lyford Cay.

Namaste Technologies owns and operates online retail sites with a presence in many nations. The Company is an international leader in delivery systems for dry herbs, which can include medicinal cannabis where legally available. Through vaporizer sales and the selling of glass and pipes and other dry herb related paraphilia, Namaste has a very strong channel to sell to end consumers once it is legalized globally.

Namaste has acquired Cannmart, Inc. This is a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program). Through Cannmart, Namaste Technologies is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market.  

Namaste is in the final stages of its Cannmart license to gain approval to distribute cannabis in Canada. Legalization is in the final stages in Canada. It received approval in the Canadian Senate yesterday.

Namaste Technologies is also active in product development and manufacturing. It will launch the Grizzly Eclipse Vaporizer soon.

Namaste has majority market share in Europe and Australia. The Company has operations in the United Kingdom, the United States, Canada and Germany. Additionally, it has opened new supply channels into developing markets. This includes Brazil, Mexico, and Chile.

This week, Namaste Technologies announced that its wholly-owned subsidiary, Cannmart received its Access to Cannabis for Medical Purposes Regulations (ACMPR) Production License. Under the guidelines from Health Canada, Cannmart may now place initial orders with ACMPR licensed producers.

Sean Dollinger, Namaste Technologies’ President and Chief Executive Officer, said, “This important milestone represents an incredible achievement for Namaste and its shareholders. Receipt of the ACMPR Production License not only validates Namaste’s strategy but it serves as a critical component of the Company’s anticipated growth moving forward.  We are very proud to have met our goal of receiving our ACMPR medical cannabis Production License from Health Canada as we look to explore the tremendous opportunities that exist in the Canadian cannabis market.”

Yesterday, Namaste Technologies announced that it signed a non-binding Terms Sheet with PharmaCann Pty Ltd.  Namaste will participate in an investment to purchase a 10 percent equity position in PharmaCann.

At present, PharmaCann operates with existing licenses to import, export, and also wholesale medical cannabis issued by the Australian Government Department of Health. Namaste Technologies’ investment in PharmaCann will be used by PharmaCann to proceed with its application to further secure a cultivation license.

Namaste Technologies, Inc. (NXTTF), closed Tuesday's trading session at $2.37, up 3.95%, on 2,947,076 volume with 2,654 trades. The average volume for the last 3 months is 1,161,328 and the stock's 52-week low/high is $0.1469/$3.47149.


Trican Well Service Ltd. (TOLWF)

InvestorsHub, TalkMarkets, Street Insider, Dividend Investor, TipRanks, GuruFocus, Morningstar, Capital Cube, YCharts, Barchart, MarketWatch, Seeking Alpha, Stockhouse,,, 4-Traders,, and Investors Hangout reported on Trican Well Service Ltd. (TOLWF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Established in 1979, Trican Well Service Ltd. delivers service and technology throughout a company’s well's life cycle. An oilfield services enterprise, the Company provides various specialized products, equipment, services, and technology for use in the drilling, completion, stimulation, and reworking of oil and gas wells mainly in Canada. Trican Well Service is headquartered in Calgary, Alberta. The Company lists on the OTC Markets Group’s OTCQB.

Trican Well Service is a Canadian market leader in fracturing services. The Company is also a Canadian market leader in cementing services. Its supporting service lines include coil tubing, nitrogen, acid, water management services and industrial services.

In 2017, Trican Well Service acquired Canyon Technical Services Ltd. Trican will explore adding or growing additional service lines in Canada after Canyon Technical Services is completely integrated.

For Q4 2017, 83 percent of revenue was from liquids rich and oil plays. Only 17 percent of revenue was from dry gas customers. Roughly half of Trican’s manned fracturing equipment is committed throughout this year. The Company’s emphasis is on driving better crew efficiency and increased sand per well to propel better profitability.

Trican Well Service will license its technology in the United States and in International markets for additional growth. This will be to licensed sand supplier and chemical suppliers in North America.

Trican will sell selective chemistry in the United States and Canada It will also sell silica dust control product in other industries. Trican is exploring technology and product sales around the world.

The Company has its MVP Frac™. This is a patented chemical solution. It decreases proppant settling in slick water fracs. The Company has signed one license in the United States with a sand supplier. Trican is pursuing additional licenses.

In addition, Trican has its CleanTRACK™. This is a patented dust control product being utilized to control dust on lease roads, lease sites, as well as all dirt roads.

For 2017, Trican Well Service reported Adjusted Operating Income for the year of $183.3 million. This represents a considerable improvement over the Adjusted Operating Loss of $37.4 million in 2016.  This significant change was driven by a stronger operating environment. It was also driven by a cost structure that was improved through the downturn.

Trican Well Service Ltd. (TOLWF), closed Tuesday's trading session at $1.8987, up 0.99%, on 2,411 volume with 11 trades. The average volume for the last 3 months is 10,253 and the stock's 52-week low/high is $1.8439/$4.1802.


Humanigen, Inc. (HGEN)

TradingView, Investopedia, InvestorsHub, OTC Markets, AmigoBulls, Barchart, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. centers on advancing medicines for patients with neglected and rare diseases via innovative, accelerated business models. Lead compounds in the Company’s portfolio include the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Derived from its Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Humanigen is headquartered in Brisbane, California.

The Company pursues innovative science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Lenzilumab has potential for treatment of various rare diseases. These include hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that drives the growth of certain hematologic malignancies.

The other key asset in the Company’s monoclonal antibody portfolio, ifabotuzumab, has been dosed in the first patient in an investigator-sponsored Phase 0/1 radio-labeled imaging trial in glioblastoma multiforme (GBM). GBM is a particularly aggressive and deadly brain cancer.

Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created utilizing Humanigen's proprietary Humaneered® technology.

Last week, Humanigen announced that it completed patient enrollment in the continuing Phase 1 trial of lenzilumab in patients with previously treated chronic myelomonocytic leukemia (CMML). The design of the Phase 1, multi-center, open-label, dose-escalation trial is to evaluate the maximum tolerated dose, safety and tolerability of single-agent lenzilumab in 12 patients with CMML who are relapsed, refractory to, or intolerant to standard-of-care treatments. In addition, the trial will provide more data on pharmacokinetics and pharmacodynamics.

Mr. Cameron Durrant, M.D., Chairman and Chief Executive Officer of Humanigen, said, “Full enrollment of the CMML trial shows our unflinching commitment to execution on the important work to progress our assets, strengthen our company and to drive value for patients and all our stakeholders. We look forward to more milestones quickly ahead as we compile an interim report on the safety of lenzilumab in CMML and we initiate a planned Phase 1b/2 study to assess lenzilumab’s potential to prevent and/or reduce neurotoxicity related to CAR-T cancer therapy.”

Humanigen, Inc. (HGEN), closed Tuesday's trading session at $0.714, up 8.02%, on 9,196 volume with 11 trades. The average volume for the last 3 months is 5,692 and the stock's 52-week low/high is $0.125/$1.00.


Drone USA, Inc. (DRUS)

Penny Stock Tweets, Market Screener, MicroCap Daily, The Street, Market Exclusive, Stock News Now, Wallet Investor, Stock Daily Review, Business Wire, OTC Markets, Oracle Dispatch, Simply Wall St, InvestorsHub, 4-Traders, and Stockhouse reported on Drone USA, Inc. (DRUS), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Drone USA, Inc. is a developer, manufacturer, and distributor of low altitude drones and related technologies. Its main target markets include U.S. police, firemen, and the U.S. Government. Drone USA designs and builds high quality drones, training, insurance, replacement parts and anything a customer requires to ensure their missions are successful. All the Company’s products will be manufactured and assembled in the United States. OTCQB-listed, Drone USA is based in West Haven, Connecticut.

The Company’s services include Real Estate Photography for Advertisement; Utility Inspection; and Construction Inspection & Photo/Video Marketing. Additionally, Services include Precision Agriculture; Search & Rescue Assistance; and Fire Hot Spot Location. All of its drones operate with closed encrypted software. This is for national security purposes.

Howco Distributing Co., of Vancouver, Washington, is a subsidiary of Drone USA. Howco Distributing is the Company’s manufacturing supply chain segment. Howco Distributing is a first-class supplier of spare and replacement parts to the United States Federal Government and commercial customers around the world. Howco is an authorized provider for hundreds of manufacturers and original equipment manufacturers (OEMs).

Howco Distributing's services include bid solicitation, contract management, packaging and logistics for construction, transportation, mining and heavy equipment spare and replacement parts to customers internationally using a broad assortment of supply chain solutions.

Drone USA is working on three profitable growth strategies. These are Police & U.S. Government drone sales; increasing Howco Distributing’s product line and reach; and acquiring companies that expand Drone USA’s product and customer base.

Last week, Drone USA announced that its subsidiary, Howco Distributing, received 256 contracts totaling $383,222 from the U.S. Army over the past 10 days.

Mr. Michael Bannon, Drone USA's Chief Executive Officer, said, "I am proud of our Howco team. As I focus on acquisitions and organically growing our Drone and Insulation Jacket businesses on the East Coast, they are doing a great job. In addition, today we executed on our plan to grow Howco's supplier base. The more supplier relationships we secure, the more contracts we will bid."

Furthermore, Drone USA announced last week that it received a purchase order to supply Kentucky's Division of Highway Design with a surveying drone.

Drone USA, Inc. (DRUS), closed Tuesday's trading session at $0.0052, up 8.33%, on 20,914,333 volume with 222 trades. The average volume for the last 3 months is 56,241,243 and the stock's 52-week low/high is $0.00394/$0.21999.


Esports Entertainment Group, Inc. (GMBL)

Real Pennies reported earlier on Esports Entertainment Group, Inc. (GMBL), and today we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Esports Entertainment Group, Inc. is a next generation, licensed, online gambling business specifically centered on eSports wagering. Its intention is to offer wagering on eSports events in a fully licensed, regulated, and secured platform to the global eSports audience, excluding the United States. Esports Entertainment Group has offices in St. Mary's, Antigua and Barbuda.

In essence, Esports Entertainment Group is a licensed online gambling company with a particular focus on eSports wagering and 18+ gaming. A team of industry and technical experts from the online gambling and video game industries, and e-Sports, marketing, legal, and financial professionals lead Esports Entertainment Group.

Esports is focusing on launching its online Esports gambling platform. This platform will be completely licensed and the highest regulated esports gambling site internationally.

Additionally, Esports intention is to offer users around the world the ability to participate in multi-player video games tournaments online for cash prizes. At present, the Company is developing several play money websites and its real money wagering website.

Esports Entertainment Group has been issued a Client Provider Authorization Permit by the Kahnawake Gaming Commission. Esports has applied for an Interactive Wagering License with the Financial Services Regulatory Commission of Antigua and Barbuda to conduct real money interactive gaming on an international basis from centers in Canada and Antigua.

Moreover, Esports has an agreement with CAMS, LLC to provide worldwide electronic payment and risk management solutions. Esports has a peer-to-peer wagering system. It will provide real money betting exchange style wagering on all professional eSports events.

Esports Entertainment Group announced in October of 2017 the execution of a Letter of Intent (LOI) to acquire all of the issued and outstanding securities of Ardmore Investments SP. Z O.O. Ardmore is a subsidiary of Switzerland based gambling software developer Swiss Interactive Software GmbH. Also, Esports has received its Curacao eGaming License.

This week, Esports Entertainment Group announced the launch of VIE ( The Company states that this is the world’s safest, most secure and transparent esports wagering platform.

VIE offers bet exchange style wagering on esports events in a licensed, regulated and secured platform to the worldwide esports audience. This excludes jurisdictions such as the United States, which prohibit online gambling.

The bet exchange model provides for player versus player betting (PVP). The house takes a small percentage of each wager. This is versus a sports book model that pits the player versus the house.

Esports Entertainment Group, Inc. (GMBL), closed Tuesday's trading session at $0.62, up 1.64%, on 8,599 volume with 8 trades. The average volume for the last 3 months is 16,168 and the stock's 52-week low/high is $0.1469/$2.65.


MariMed, Inc. (MRMD)

OTC Markets, Investors Hub, and DailyMarijuanaObserver reported earlier on MariMed, Inc. (MRMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. MariMed is based in Newton, Massachusetts.

MariMed is focusing exclusively on serving the fast expanding $7 billion legal cannabis industry. MariMed in 2017 announced the purchase of a 137,500 sq. ft. industrial building on 17 acres at 167 John Vertente Blvd., in the New Bedford, Massachusetts industrial park for a purchase price of $6,895,000. MariMed will develop roughly 70,000 sq. ft. into a full service, state-of-the-art medical cannabis cultivation and production facility. This has been leased to ARL Healthcare, Inc. (ARL), a Massachusetts not for profit corporation.

MariMed assisted ARL Healthcare in its successful application to be awarded a Massachusetts Registered Marijuana Dispensary (RMD) License for cultivation, production, and dispensing of medical cannabis. MariMed will assist ARL Healthcare in the development and ongoing management of the cultivation and manufacturing facility.

MariMed is on the vanguard of medical research. The Company is working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in many states. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, and dispensary operations.

The Company provides a complete range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness. As Cannabis experts, it specializes in supporting the development of high quality state-licensed, medical cannabis dispensaries and cultivation facilities.

MariMed’s services include application assistance, real estate and safe access, build-out and continuing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, as well as product licensing opportunities.

This past November November, MariMed announced that it acquired the rights to the intellectual property (IP), formulations, recipes, proprietary equipment, and expertise of Betty’s Eddies from Icky Enterprises LLC. This acquisition enables MariMed to further expand its unique, industry-leading Kalm Fusion™ precision dosed medical cannabis-infused product line. Betty’s Eddies is a line of fruit chews handcrafted and naturally sweetened with premier all natural ingredients and non-GMO organic fruits and vegetables.

Recently, MariMed announced that it and its wholly-owned subsidiary Hartwell Realty LLC, on January 25, 2018 received from the Town of Middleborough, Massachusetts, a Special Permit to begin build-out of the 8,000 sq. ft. building at 29 Harding St., Middleborough that MariMed purchased for $1.5 million in August of 2017.  MariMed will immediately commence the renovation into a secure, state-of-the-art medical cannabis dispensary expected to serve thousands of state-registered medical cannabis patients.

Last week, MariMed announced that it raised  $2.828 million in equity through the sale of its Restricted Common Stock in private placements between October 30, 2017 and January 24, 2018 at prices averaging 15 percent below the market price. These funds were used for the ongoing development of MariMed cannabis facilities in Maryland and Massachusetts.

MariMed, Inc. (MRMD), closed Tuesday's trading session at $2.92, up 6.96%, on 1,482,272 volume with 1,884 trades. The average volume for the last 3 months is 353,162 and the stock's 52-week low/high is $0.201/$4.07.


AXIM Biotechnologies, Inc. (AXIM)

Insider Financial, Market Screener, TopPennyStockMovers, BioSpace, Daily Mariunuana Observer, CFN Media Group, Promotion Stock Secrets, Wallet Investor, SmallCapVoice, and Simply Wall St reported on AXIM Biotechnologies, Inc. (AXIM), and we also report on the Company, here at the QualityStocks Daily Newsletter.

AXIM Biotechnologies, Inc. is a biotechnology company listed on the OTCQB. It concentrates on the research, development, and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The Company discovers and brings to market unique solutions via research and development (R&D), strategic partnerships, and acquisitions through setting the green standard in the industrial hemp industry. AXIM Biotechnologies has its headquarters in New York, New York.

Medical Marijuana, Inc. (MJNA) is a major investor in AXIM. Medical Marijuana, Inc. (MJNA) announced in February 2018 that its major investment company AXIM Biotechnologies successfully executed its first-ever proprietary current good manufacturing practices (cGMP) methodology in the extraction and microencapsulation of cannabinoid molecules for an assortment of pharmaceutical delivery formats from cGMP-produced medicinal cannabis. This breakthrough makes AXIM the only Company globally with the ability to harness the proprietary procedure and provide Active Pharmaceutical Ingredients (APIs) of such purity from naturally extracted cGMP sources.

AXIM Biotechnologies’ emphasis is on innovative, proprietary delivery mechanisms for the introduction of cannabinoids and finding solutions for conditions for which there is currently no effective treatment. It is advancing its patented controlled-release cannabinoid gum in studies encompassing several indications.

The Company’s IP (Intellectual Property) portfolio now includes two fully issued patents – one patent permitting the use of CBD (cannabidiol) in controlled-release, functional chewing gum, and another patent for chewing gum containing natural and synthetic cannabinoids for the treatment of pain, and 15 patent applications in differing stages of approval.

AXIM Biotechnologies’ flagship CanChew Plus® contains 10mg of cannabidiol (CBD) obtained from industrial hemp plants. Moreover, AXIM has its CanChew+ 50®. This product contains 50 mg of CBD. CanChew+ 50®is undergoing clinical trials in patients with IBS (Irritable Bowel Syndrome).

The Company’s pipeline of IP protected cannabinoid-based products additionally includes MedChew Rx™. This THC/CBD cannabinoid controlled-release chewing gum is to address pain and muscle spasticity in multiple sclerosis (MS) patients. It is the world’s first patented cannabinoid controlled-release chewing gum.

Last month, AXIM Biotechnologies announced positive results from stability and dissolution tests performed on its main drug candidate, MedChew Rx®, which will undergo clinical trials for the treatment of pain and spasticity in Multiple Sclerosis (MS) patients. Results showed that the primary Active Pharmaceutical Ingredients (APIs) in MedChew Rx™ remained stable throughout the test and that the availability of the APIs was more than 90 percent.

Last week, AXIM Biotechnologies announced that it signed a Letter of Intent (LOI) with Impression Healthcare Limited for exclusive distribution of all AXIM products throughout Australia and New Zealand. Impression Healthcare is Australia’s largest home dental impression company.

With this LOI, both companies will work to co-develop new products, first for pre-clinical and Phase 1 trials (among other clinical trials). This includes an oral rinse liquid targeted for the treatment of oral mucositis, strep throat, oral infections and gum disease.

AXIM Biotechnologies, Inc. (AXIM), closed Tuesday's trading session at $1.98, up 1.54%, on 169,981 volume with 201 trades. The average volume for the last 3 months is 86,646 and the stock's 52-week low/high is $1.70/$10.289.


The QualityStocks Company Corner

PreveCeutical Medical Inc. (CSE: PREV) (OTC: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is celebrating the achievement of several key milestones in the development of the company’s proprietary Sol-gel program for the nasal delivery of select medications, where those medications can be expected to effectively reach the nervous system in order to accomplish their purposes in treating conditions ranging from anxiety to head concussion injuries, a company officer told market reporting outlet Proactive Investors Limited.

PreveCeutical Medical Inc. (CSE: PREV) (OTC: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.046, up 53.33%, on 2,291,759 volume with 230 trades. The average volume for the last 3 months is 654,169 and the stock's 52-week low/high is $0.002/$0.20.

Recent News


Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

CannabisNewsAudio announces the Audio Press Release (APR) titled “The CBD Bonanza on the Horizon,” featuring Earth Science Tech Inc. (OTCQB: ETST). To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $1.14, up 15.15%, on 244,014 volume with 310 trades. The average volume for the last 3 months is 15,367 and the stock's 52-week low/high is $0.324/$1.62.

Recent News


Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings Inc. (OTC: GRYN) (“the Company”), a full-scope, premium cannabis company targeting the high-end medical and adult-use recreational markets, today announces its strategic acquisition of the Canna Brands Portfolio. Also today, NetworkNewsWire released a report on the company detailing how GRYN is targeting the high-end medical and adult-use recreational market with cannabis grown by an enhanced hybrid aeroponic method.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.4355, up 9.48%, on 99,829 volume with 37 trades. The average volume for the last 3 months is 62,290 and the stock's 52-week low/high is $0.0099/$0.50.

Recent News



The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL) (the “Company”), the cannabis industry's new standard of technology, today announces its joint venture marketing agreement with Nichols Publishing Company, the publishers of Garden & Greenhouse and Professional Marijuana Grower magazines that will expand the reach of NUGL’s user-friendly cannabis and indoor gardening search app as it becomes the industry’s go-to-app for unbiased client reviews, retail shop and dispensary listings, locations of favorite cannabis brands and in-depth company profiles. Also today, NUGL was featured in the Venture Market News for September 18, 2018. Full press release.

NUGL Inc. (NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.58, up 7.48%, on 238,080 volume with 215 trades. The average volume for the last 3 months is 133,681 and the stock's 52-week low/high is $0.405/$1.79.

Recent News


CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is the focus of a recently-released corporate summary from leading independent small cap media portal To view the full press release, visit:

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.6271, off by 1.63%, on 139,286 volume with 52 trades. The average volume for the last 3 months is 365,762 and the stock's 52-week low/high is $0.40/$0.836.

Recent News


Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

New manufacturers are joining the race to design electric vehicles, accelerating a revolution in the car market that could result in strong lithium demand as a battery ingredient. Standard Lithium (TSX.V: SLL) (OTC: STLHF) (STLHF Profile) is one of several companies that are innovating to meet this demand scenario by developing new technology that could unlock a major supply source untapped in Arkansas.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.


Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $1.138, off by 0.18%, on 139,384 volume with 150 trades. The average volume for the last 3 months is 34,625 and the stock's 52-week low/high is $0.604/$2.23.

Recent News


DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company (the “Company”), announced CEO Milton “Todd” Ault will present at The MicroCap Conference in New York City. The event is being held on October 1-2, 2018 at the JW Marriott Essex House.

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.4338, up 2.26%, on 669,540 volume with 1,439 trades. The average volume for the last 3 months is 1,769,704 and the stock's 52-week low/high is $0.3889/$5.9499.

Recent News


Sunniva, Inc. (CSE: SNN) (OTC: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF), a company that cultivates, processes and distributes cannabis, has announced its second quarter financial results, detailing milestones and achievements both for the second quarter and the first half of 2018 ( Recapping the company’s developments over the past six months, CEO Dr. Anthony Holler said that Sunniva has moved closer toward its goal of full vertical integration, which is a key company strategy.

Sunniva, Inc. (CSE: SNN) (OTC: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $5.15, up 8.42%, on 89,936 volume with 191 trades. The average volume for the last 3 months is 60,138 and the stock's 52-week low/high is $3.609/$16.00.

Recent News


Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (Nasdaq:YGYI), a leading omni-direct lifestyle company, announced that it has expanded its footprint in the cruise line industry by adding another prestigious brand to its hospitality business.  CLR is proud to now be roasting and serving its coffee to the entire crew and staff of another top cruise line in the hospitality industry.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $4.0966, off by 0.57%, on 23,100 volume with 89 trades. The average volume for the last 3 months is 19,415 and the stock's 52-week low/high is $3.1674/$5.50.

Recent News


Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom™ (CSE: CHOO) (OTCQB: CHOOF) (the "Company" or "Choom") an emerging, fully-integrated cannabis company, is pleased to announce that it has applied for a master retail license (the "License") in Manitoba's Request for Proposal ("RFP") to sell recreational cannabis coming October 17th.  The License would give Choom the capability to operate retail cannabis stores within the province, as well as, an e-commerce platform.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.8891, off by 0.70%, on 462,986 volume with 463 trades. The average volume for the last 3 months is 402,915 and the stock's 52-week low/high is $0.18/$1.129.

Recent News


Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

Canada-based Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) has released the initial results of its latest core-sampling campaign at an Argentine exploration site believed to contain significant quantities of gold and silver.

Marifil Mines Ltd. (TSX.V: MFM) (OTC: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.10, off by 0.99%, on 43,554 volume with 11 trades. The average volume for the last 3 months is 18,079 and the stock's 52-week low/high is $0.009/$0.165.

Recent News


First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

A tightening market and projected shortages of cobalt – a key battery metal used in everything from smartphones to electric vehicles, electronics and defense systems – is generating concern around the world, industry analysts report. Cobalt prices have tripled over the past two years, posing a threat to how quickly the electric vehicle market can grow in the near future, as noted in an article published by Bloomberg ( Vertically integrated pure-play cobalt company First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF) (ASX: FCC) has consciously and strategically placed its efforts into its North American assets such as the Iron Creek Project in Idaho and the Greater Cobalt Project in the Canadian Cobalt Camp, which holds more than 50 past producing mines.

First Cobalt Corp. (TSX.V: FCC) (OTC: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.2744, up 0.15%, on 123,330 volume with 51 trades. The average volume for the last 3 months is 221,267 and the stock's 52-week low/high is $0.1983/$1.3041.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer. BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.089, off by 11.00%, on 45,847 volume with 2 trades. The average volume for the last 3 months is 16,481 and the stock's 52-week low/high is $0.068/$0.139.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.